The role of long noncoding RNA HOTAIR in the acquired multidrug resistance to imatinib in chronic myeloid leukemia cells

Hematology. 2017 May;22(4):208-216. doi: 10.1080/10245332.2016.1258152. Epub 2016 Nov 22.

Abstract

Objectives: Imatinib, a breakpoint cluster region-Abelson murine leukemia tyrosine kinase inhibitor, has revolutionized the treatment of chronic myelogenous leukemia (CML). However, the development of multidrug resistance (MDR) limits the clinical application of imatinib. In this study, we aimed to investigate the mechanisms of long noncoding RNA (lncRNA) HOTAIR in CML resistance to imatinib.

Methods: Thirty-four CML patients were divided into multidrug resistance protein 1 (MRP1)-low and MRP1-high groups according to the median expression. Real-time PCR (qPCR) was used to detect the expression of lncRNA HOTAIR in CML patients, and MTT assay and flow cytometry assay were employed to detect the biological function of silencing lncRNA HOTAIR on the cell survival rate and apoptotic rate. An imatinib-resistant human CML cell line K562 (K562-R) was established, and western blot was used to detect the impact of lncRNA HOTAIR on the activation of PI3K/Akt signaling pathway.

Results: Our results showed that lncRNA HOTAIR was greatly upregulated in the MRP1-high patients as well as in the K562-imatinib-resistant cells compared with control. Knockdown of HOTAIR expression downregulated the MRP1 expression levels in the K562-imatinib cells and resulted in higher sensitivity to the imatinib treatment. In addition, the activation of PI3K/Akt was greatly attenuated when HOTAIR was knocked down in K562-imatinib cells.

Discussions: These data suggest that the knockdown of HOTAIR may play a crucial role in improving acquired resistance to imatinib in CML K562-R cells via PI3K/Akt pathway.

Conclusions: LncRNA HOTAIR modulates CML cell MDR in a PI3K/Akt-dependent way.

Keywords: Chronic myeloid leukemia; PI3K/Akt pathway; imatinib resistance; long noncoding RNA HOTAIR.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / pharmacology
  • Drug Resistance, Multiple
  • Female
  • Humans
  • Imatinib Mesylate / pharmacology*
  • K562 Cells
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism
  • Male
  • Middle Aged
  • Multidrug Resistance-Associated Proteins / biosynthesis
  • Multidrug Resistance-Associated Proteins / genetics
  • Multidrug Resistance-Associated Proteins / metabolism
  • Phosphatidylinositol 3-Kinases / metabolism
  • Protein Kinase Inhibitors / pharmacology
  • Proto-Oncogene Proteins c-akt / metabolism
  • RNA, Long Noncoding / biosynthesis
  • RNA, Long Noncoding / genetics*
  • Young Adult

Substances

  • Antineoplastic Agents
  • HOTAIR long untranslated RNA, human
  • Multidrug Resistance-Associated Proteins
  • Protein Kinase Inhibitors
  • RNA, Long Noncoding
  • Imatinib Mesylate
  • Phosphatidylinositol 3-Kinases
  • Proto-Oncogene Proteins c-akt
  • multidrug resistance-associated protein 1